Transcatheter Aortic Valve Replacement Program in the Post–Food and Drug Administration Approval Era: Early Outcomes at an Academic Medical Center

Conclusions: Transcatheter aortic valve replacement is a viable option for patients at very high risk for surgical intervention in the post–Food and Drug Administration approval era. Real-world results comparable with published outcomes from experienced centers involved in the PARTNER trial can be achieved.
Source: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Original Articles Source Type: research